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Editor\'s key points•Clinical Frailty Scale (CFS) scores indicating mild frailty have been proposed to guide ICU admission for UK patients with coronavirus disease 2019 (COVID-19) pneumonia.•However, the impact of frailty on mortality with (non-COVID-19) pneumonia is unknown.•The authors examined the relationship between CFS and mortality in patients requiring ICU for (non-COVID-19) pneumonia, using a large Australian and New Zealand database on critical care admissions.•Only CFS scores ≥7 were associated with higher (adjusted) mortality.•These data suggest that CFS scores ≥5 alone are not useful for guiding the allocation of critical care resources.

Frailty, a multiply determined state of decline in health imparting vulnerability to stress, is present in 30% of patients admitted to the ICU.[@bib1] It is associated with higher mortality, longer ICU and hospital lengths of stay, increased discharge to residential care, and greater health costs.[@bib1], [@bib2], [@bib3], [@bib4] During the coronavirus disease 2019 (COVID-19) pandemic, patient frailty has been advocated as a criterion to triage ICU admission in the presence of pneumonia.[@bib5] The Clinical Frailty Scale (CFS),[@bib6] a widely used, simple, and valid frailty screening measure in use in critical illness, is being used for this purpose. Specifically, in the UK, the National Institute for Health and Care Excellence initially recommended that a CFS ≥5, corresponding to mild frailty, be considered as a threshold above which ICU admission could be potentially initially be declined. This guidance was intended to help ration ICU resources should demand for beds exceeds supply.[@bib5] This advice was subsequently revised to advise caution in applying the CFS in younger patients and in those with stable long-term disabilities, and hence to apply it only in patients aged \>65 yr.[@bib7]

However, evidence supporting triage recommendations for pneumonia requiring critical care support is lacking. Although the commonest complication of COVID-19 disease resulting in ICU admission is hypoxic respiratory failure secondary to pneumonia, the impact of frailty on outcomes amongst patients with pneumonia admitted to the ICU is unclear, and the relevance of the 65-yr-old cut-off advocated for considering the CFS currently is unknown.

Accordingly, we conducted a multicentre retrospective cohort study of patients admitted with pneumonia to ICUs in Australia and New Zealand to evaluate the association of frailty with in-hospital mortality and other outcomes. In doing so, our aim was to provide data to inform guidelines on the use of the CFS as a triage tool and on the appropriateness of the triage threshold of a CFS ≥5 recommended in current guidelines both overall and in those aged \>65 yr.

Methods {#sec1}
=======

Study design {#sec1.1}
------------

This was a retrospective cohort study, using previously described methods.[@bib8] Population based data were collected by the Australian and New Zealand Intensive Care Society (ANZICS) Centre for Outcome and Resource Evaluation, which manages the ANZICS Adult Patient Database (APD), including data on ≥80% of all patients admitted to ICUs in Australia and New Zealand.[@bib9] Data are subject to automated validity checks, with data collectors undergoing regular quality assurance review and training. Data dictionary use is mandated. This clinical registry is used for benchmarking amongst contributing ICUs. Ethics approval was provided by the Alfred Hospital Human Research Ethics Committee (584/18).

Inclusion criteria {#sec1.2}
------------------

All patients with pneumonia aged ≥16 yr admitted to an ICU between January 1, 2018 and September 31, 2019 were included.

Exclusion criteria {#sec1.3}
------------------

We excluded patients who were admitted to the ICU for the sole purpose for organ donation or palliative care. In the event of multiple ICU admissions during a hospital stay, only the first was included.

Data collection {#sec1.4}
---------------

Patient characteristic data were age, sex, diagnosis (defined by the Acute Physiology and Chronic Health Evaluation \[APACHE\] III-j diagnosis codes), medical treatment limitation order (either patient initiated or because of medical futility), and illness severity scores (APACHE II and III-j[@bib10] and Australian and New Zealand Risk of Death \[ANZROD\] scores).[@bib11] Patients were defined as having pneumonia using APACHE III-j admission diagnoses of bacterial or viral pneumonia.

Explanatory variable: frailty {#sec1.5}
-----------------------------

The Canadian Study of Health and Aging CFS was used for frailty measurement, a 9-point judgement-based categorical scale, which is inclusive---everyone has a place on it. This scale has demonstrated validity and reliability in frailty assessment in ICU patients and other populations.[@bib2] ^,^ [@bib6] The modified eight-category CFS is the most utilised frailty assessment in the critically ill.[@bib12] This scale ranges from a CFS=1 (very fit), 2 (well), 3 (managing well), 4 (vulnerable), 5 (mildly frail), 6 (moderately frail), 7 (severely frail) to 8 (very severely frail).[@bib6] Frailty scores were both dichotomised as non-frail (CFS 1--4) or frail (CFS 5--8) according to accepted definitions,[@bib2] with the frail cohort further considered in terms of mild/moderate frailty (CFS 5--6) and severe/very severe frailty (CFS 7--8). Frailty is a non-mandatory variable in the ANZICS APD, collected since 2017, and is defined as the patient\'s level of physical function 2 months before hospital admission.

Primary outcome {#sec1.6}
---------------

The primary outcome was in-hospital mortality.

Secondary outcomes {#sec1.7}
------------------

We assessed the following secondary outcomes: discharge to nursing home/chronic care, survival to community discharge, organ support within the ICU (mechanical and noninvasive ventilation, renal replacement therapy, vasoactive infusion, and extracorporeal membrane oxygenation), and ICU bed day occupancy.

Statistical analysis {#sec1.8}
--------------------

Data were examined for normality and compared between groups using χ^2^ tests (equal proportion), Student\'s *t*-tests (parametric data), or Wilcoxon rank-sum tests, reporting results as *n* (%), means (standard deviation), and medians (inter-quartile range \[IQR\]), respectively.

The relationship between frailty and outcome was determined fitting hierarchical logistic regression using the PROC GLIMMIX procedure with patients nested within sites and site treated as a random effect with results reported as marginal odds ratios (ORs) (95% confidence interval \[CI\]). Model covariates include age, gender, pneumonia type (viral or bacterial), mechanical ventilation, and illness severity, with heterogeneity determined by fitting first-order interactions with frailty. Patient illness severity was measured by the ANZROD score, a locally derived highly discriminatory score for mortality in Australian and New Zealand ICU patients.[@bib9] ^,^ [@bib11] ^,^ [@bib13] Whilst ANZROD ordinarily includes patient age, to model age separately, the age component within ANZROD was removed. As frailty is an ordinal score with eight categories, it was initially modelled as a categorical variable and then secondly as a continuous variable, where evidence of linearity was observed to exist. After a significant interaction between CFS and age, exploratory analyses were performed on patients dividing age into 10 yr blocks.

Predefined subgroup analysis was performed on patients determined by pneumonia type (viral *vs* bacterial), age (\>65 yr), and mechanical ventilation. All analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC, USA), and a two-sided *P*-value of 0.05 was used to indicate statistical significance.

Results {#sec2}
=======

Subject characteristics {#sec2.1}
-----------------------

Over the study period, 9353 patients with pneumonia aged ≥16 yr were admitted to 170 ICUs; 671 were excluded (574 readmissions, 38 palliative care admissions, and 59 missing hospital outcome), of whom 5607/8682 had complete frailty data. In total, 1852/5607 (33%) patients were classified as frail, which increased in frequency with advancing age ([Fig. 1](#fig1){ref-type="fig"} ). Patients classified as frail were older with higher illness severity scores ([Table 1](#tbl1){ref-type="table"} ). Patients with frailty also had more chronic co-morbidities (particularly chronic respiratory disease) and were more likely to have treatment limitations in place on admission to the ICU ([Table 1](#tbl1){ref-type="table"}; [Supplementary Tables 2 and 3](#appsec1){ref-type="sec"}).Fig 1Distribution of Clinical Frailty Scale (CFS) scores, stratified by age.Fig 1Table 1Baseline patient characteristics of included patients. ANZROD, Australian and New Zealand Risk of Death; APACHE, Acute Physiology and Chronic Health Evaluation; IQR, inter-quartile range; [sd]{.smallcaps}, standard deviation.Table 1CharacteristicAll patients (*n*=5607)Frail patients (*n*=1852)Non-frail patients (*n*=3755)*P*-valueAge (yr), mean ([sd]{.smallcaps})63.8 (17.6)70 (15.6)60.8 (17.7)\<0.0001Sex (men)3041 (54.2%)968 (52.3%)2073 (55.2%)0.038 Any co-existing condition2377 (42.4%)1115 (60.2%)1262 (33.6%)\<0.0001 Chronic respiratory1150 (20.5%)617 (33.3%)533 (14.2%)\<0.0001 Chronic cardiovascular592 (10.6%)300 (16.2%)292 (7.8%)\<0.0001 Metastatic cancer217 (3.9%)104 (5.6%)113 (3.0%)\<0.0001 Immunosuppression573 (10.2%)210 (11.3%)363 (9.7%)0.05 Chronic renal failure266 (4.7%)138 (7.5%)128 (3.4%)\<0.0001 Chronic liver disease90 (1.6%)39 (2.1%)51 (1.4%)0.036 Liver cirrhosis85 (1.5%)39 (2.1%)46 (1.2%)0.011APACHE II score, mean ([sd]{.smallcaps})17.4 (6.8)19.2 (6.4)16.5 (6.8)\<0.0001APACHE III-j score, mean ([sd]{.smallcaps})56.7 (21.5)61.5 (19.6)54.3 (21.9)\<0.0001ANZROD, median (IQR)8.0% (3.6--19.1%)14.6% (6.7--29.4%)6.1% (2.9--13.5%)\<0.0001ANZROD (age component removed), median (IQR)7.0 (3.5--15.8)11.6 (5.4--23.8)5.6 (3.0--11.8)\<0.0001Treatment limitations on admission1051 (18.7%)710 (38.3%)341 (9.1%)\<0.0001Hospital admission source Home4263 (76.0%)1378 (74.4%)2885 (76.8%)0.045 Chronic care/palliative care/nursing home95 (1.7%)76 (4.1%)19 (0.5%)\<0.0001 Transfer from other acute hospital1144 (20.4%)360 (19.4%)784 (20.9%)0.21 Mental health37 (0.7%)23 (1.2%)14 (0.4%)\<0.0001 Rehabilitation8 (0.2%)4 (0.2%)4 (0.1%)0.45 Missing60 (1.1%)11 (0.6%)49 (1.3%)0.015Viral pneumonia1261 (22.5%)352 (19.0%)909 (24.2%)\<0.0001

Primary outcome {#sec2.2}
---------------

Frail patients were twice as likely to die both in the ICU (unadjusted mortality: 12% \[229/1852\] *vs* 6% \[229/3755\]; *P*\<0.001) and in hospital (21% \[391/1852\] *vs* 9% \[322/3755\]; *P*\<0.001) ([Table 2](#tbl2){ref-type="table"} ).Table 2Univariable and multivariable ICU and hospital outcomes by Clinical Frailty Scale status. Multivariable analyses adjusting for site, age, sex, pneumonia type, and illness severity. CI, confidence interval; IQR, inter-quartile range; OR, odds ratio.Table 2Clinical frailty scaleNumber of patientsICU mortality, *n* (%)Hospital mortality, *n* (%)Adjusted hospital mortality, OR (95% CI)Discharge to nursing home/chronic care, *n* (%)Adjusted discharge to nursing home/chronic care, OR (95% CI)Discharge to home, *n* (%)ICU bed days, median (IQR)Hospital bed days, median (IQR)Non-frail3755229 (6.1)322 (8.6)49 (1.3)2757 (73.4)3.0 (1.7--6.0)8.2 (5.0--14.2) 12165 (2.3)6 (2.8)Reference1 (0.5)Reference185 (85.6)2.6 (1.7--5.5)6.2 (4.1--9.8) 291126 (2.9)38 (4.2)0.80 (0.32--1.98)4 (0.4)0.64 (0.07--5.84)737 (80.9)3.0 (1.6--6.2)7.7 (4.8--13.0) 3143891 (6.3)115 (8.0)1.02 (0.43--2.42)20 (1.4)1.41 (0.18--10.89)1048 (72.9)3.0 (1.7--5.9)8.5 (5.2--14.6) 41190107 (9.0)163 (13.7)1.61 (0.68--3.82)24 (2)1.72 (0.22--13.23)787 (66.1)3.1 (1.7--6.0)8.9 (5.7--15.3)Frail1852229 (12.4)391 (21.1)111 (6.0)981 (53.0)3.0 (1.7--5.7)9.6 (5.5--17.0) 572371 (9.9)112 (15.5)1.62 (0.67--3.90)27 (3.7)3.12 (0.4--24.02)405 (56.0)3.1 (1.8--6.0)9.3 (5.7--16.2) 672292 (12.8)154 (21.3)2.05 (0.85--4.91)44 (6.1)5.03 (0.66--38.45)392 (54.3)3.0 (1.8--5.4)10.0 (5.5--426) 734448 (14.0)95 (27.6)3.20 (1.31--7.81)36 (10.5)10.57 (1.38--80.95)161 (46.8)3.0 (1.6--5.7)9.8 (5.7--17.8) 86318 (28.6)30 (47.6)7.18 (2.59--19.9)4 (6.3)6.59 (0.69--62.91)23 (36.5)2.9 (1.6--6.2)7.3 (4.0--14.0)

Primary outcome: hierarchical logistic regression analysis {#sec2.3}
----------------------------------------------------------

When considered as a continuous variable, frailty remained significantly associated with hospital mortality, after adjustment for site, age, sex, pneumonia type, mechanical ventilation, and illness severity (OR: 1.30 for each point increase in CFS; 95% CI: 1.22--1.38; *P*\<0.001). Whilst the unadjusted risk of death increased with higher CFS, after multivariable adjustment, similar risk was evident in CFS Categories 4--6. ([Fig. 2](#fig2){ref-type="fig"} ). The relationship between frailty and mortality remained independent of sex, pneumonia type, mechanical ventilation, patient severity, and age ([Supplementary Tables 2 and 5](#appsec1){ref-type="sec"}).Fig 2Hospital mortality according to Clinical Frailty Scale (CFS) score. ∗Error bars for mortality are standard error of the mean, for odds ratio are 95% confidence interval. (Data in [Table 2](#tbl2){ref-type="table"} \[whole cohort\], [Supplementary Table 7](#appsec1){ref-type="sec"} \[patients ≥65 yr\], and [Supplementary Table 9](#appsec1){ref-type="sec"} \[patients mechanically ventilated\]). (a) Whole cohort, (b) age \>65 yr, and (c) mechanically ventilated.Fig 2

When considered by CFS category, the highest mortality was observed in patients with CFS=7 (28% \[95/344\]) and CFS=8 (48% \[30/63\]; [Table 2](#tbl2){ref-type="table"}). After adjustment, only these two highest frailty categories were associated with an increased risk of death over lower categories ([Table 2](#tbl2){ref-type="table"}, [Fig. 2](#fig2){ref-type="fig"}). These mortality differences remained in patients aged \>65 yr ([Fig. 2](#fig2){ref-type="fig"}; [Supplementary Tables 7 and 8](#appsec1){ref-type="sec"}; [Supplementary Fig. 1](#appsec1){ref-type="sec"}), and in patients who required mechanical ventilation ([Fig. 2](#fig2){ref-type="fig"}; [Supplementary Tables 9 and 10](#appsec1){ref-type="sec"}; [Supplementary Fig. 1](#appsec1){ref-type="sec"}).

Secondary outcomes {#sec2.4}
------------------

### ICU bed occupancy {#sec2.4.1}

Patients with CFS=7--8 accounted for 7% of all ICU bed days, compared with 24% of all ICU bed days for patients with CFS=5--6 ([Fig. 3](#fig3){ref-type="fig"} ).Fig 3Total ICU bed days occupied stratified by Clinical Frailty Scale (CFS). ∗Error bars are standard error of the mean.Fig 3

### Discharge to nursing home/chronic care {#sec2.4.2}

A total of 6% (111/1852) of patients with frailty *vs* 1% (49/3755) of patients without frailty were discharged to a nursing home/chronic care (*P*\<0.001); this was a new discharge location in 3% (59/1852) of patients with frailty *vs* 1% (33/3755) of patients without frailty, who previously resided at home (*P*\<0.001) ([Table 2](#tbl2){ref-type="table"}; [Supplementary Table 4](#appsec1){ref-type="sec"}). On multivariable analysis, the association with new chronic care discharge persisted (OR for each point increase in CFS=1.38; 95% CI: 1.19--1.60; *P*\<0.001, with no difference in slope between viral and bacterial pneumonia subtypes) ([Supplementary Table 6](#appsec1){ref-type="sec"}). Overall, 82% (1179/1445) of all patients with CFS=5--6 were discharged alive from hospital, with 3% (42/1445) newly admitted to a nursing home/chronic care residential location. In mechanically ventilated patients, 75% (195/261) of all patients with CFS=5--6 were discharged alive from hospital ([Supplementary Table 12](#appsec1){ref-type="sec"}).

### Organ support {#sec2.4.3}

Patients with frailty were less likely to be mechanically ventilated in the ICU (19% *vs* 28%; *P*\<0.001), but more likely to undergo noninvasive ventilation (55% *vs* 43%; *P*\<0.001; [Table 3](#tbl3){ref-type="table"} ). There was no difference in renal replacement therapy, but fewer patients with frailty underwent vasoactive infusions or extracorporeal membrane oxygenation ([Table 3](#tbl3){ref-type="table"}).Table 3Process of care and complications by Clinical Frailty Scale status. *P*\<0·001 for all categories, apart from renal replacement therapy (*P*=0.31).Table 3Clinical frailty scaleNumber of patients (*n*=5607)Invasive ventilation, *n* (%) (*n*=5559)Noninvasive ventilation, *n* (%) (*n*=5075)Renal replacement therapy, *n* (%) (*n*=4951)Vasoactive infusion, *n* (%) (*n*=5052)Extracorporeal membrane oxygenation, *n* (%) (*n*=4955)Non-frail3755976 (75.0)1469 (43.2)151 (4.5)1232 (36.1)30 (0.9) 121652 (24.2)66 (34.4)5 (2.6)54 (28.0)8 (4.2) 2911257 (28.5)335 (40.7)29 (3.6262 (31.8)11 (1.4) 31438382 (26.9)553 (42.3)63 (4.9)509 (38.8)8 (0.6) 41190285 (24.2)515 (47.7)54 (5.1)407 (37.7)3 (0.3)Frail1852326 (25.0)920 (54.9)73 (4.5)504 (30.7)3 (0.2) 5723154 (21.4)360 (54.2)29 (4.5)213 (32.5)2 (0.3) 6722107 (14.9)346 (53.3)30 (4.9)194 (30.8)1 (0.2) 734456 (16.3)180 (58.8)12 (4)83 (27.3)0 (0) 8639 (14.3)34 (60.7)2 (3.9)14 (26.4)0 (0)

Sensitivity analyses {#sec2.5}
--------------------

Compared with patients with missing frailty scores, patients with complete frailty data were older (median \[IQR\] age: 67 \[53--77\] *vs* 66 \[52--76\] yr) with lower APACHE III-j scores (mean: 57 *vs* 59; [Supplementary Table 1](#appsec1){ref-type="sec"}). Mortality in hospital and ICU, bed days, and ANZROD (median: 8.0% *vs* 8.5%) were similar between included and non-included patients.

Discussion {#sec3}
==========

In this population-level retrospective cohort study, we found that one-third of patients with pneumonia admitted to Australian and New Zealand ICUs were categorised as frail. Although these patients were twice as likely to die in the ICU and hospital, the adjusted increased risk of death was only observed in those with severe and very severe frailty. When considered as separate categories, lesser degrees of mild/moderate frailty (CFS=5--6) were not strongly associated with mortality; four out of five patients in these categories were discharged from hospital alive, with half discharged directly home. Patients categorised as vulnerable had a similar risk of in-hospital mortality as those categorised as mildly frail.

Based on the June 19, 2020 UK Intensive Care National Audit and Research Centre COVID-19 report, 90.4% of all COVID-19 patients admitted to UK critical care units were able to live without assistance in daily activities before ICU admission compared with only 73.6% of patients with viral pneumonia (non-COVID-19) admitted to UK critical care units from 2017 to 2019.[@bib14] These data suggest that ICU triage guidelines based on frailty are likely already being used in UK practice (integral to the definition of a CFS ≥5 is the requirement for assistance with activities of daily living). Although COVID-19 patients with a CFS ≥5 remain eligible for ICU admission under the guidelines, particularly subsequent to initial ward management and deterioration, these data imply that few of these COVID-19 affected patients with frailty are currently admitted to UK ICUs. Our findings also indicate that the increased mortality risk for ICU patients with pneumonia in the mild frailty category, who would potentially be declined ICU admission based on UK COVID-19 ICU triage recommendations, was essentially identical to the risk in the vulnerable category who would not be declined admission. Our finding that the association between frailty and mortality was less pronounced in patients aged \>65 yr further suggests caution in the use of the CFS in ICU triage in older patients with pneumonia---the target group of this guidance.

Our findings are concordant with a previous report suggesting comparatively better outcomes in critical illness for patients with mild frailty than higher categories.[@bib2] ^,^ [@bib12] However, they contrast with a recent European study of 1100 patients undergoing review by a rapid response team, in which 67% (193/287) of patients categorised as CFS 5--6 either died or remained hospitalised at 30 days, similar to outcomes for patients in higher frailty categories.[@bib15] The relevance of this study to patients with pneumonia or with COVID-19 admitted to the ICU is unclear. In our study, relatively few patients were discharged to chronic care facilities both overall and in patients aged \>65 yr. Coupled with mortality findings, these data suggest overall acceptable outcomes for patients with pneumonia, particularly at lower levels of frailty. Patients with a CFS ≥5 accounted for almost a third of ICU bed days, whereas patients with severe and very severe frailty only accounted for 7% of ICU bed days. These findings imply that adjusting the CFS threshold used for triage purposes to exclude only patients with severe or very severe frailty would result in relatively few patients with pneumonia being declined ICU admission on frailty grounds. Moreover, it would only be useful if ICU demand did not substantially exceed the number of available beds.

Alternative approaches to ICU triage during the COVID-19 pandemic have been advocated or implemented outside of the UK, incorporating both initial patient assessment and review of ICU progress over time. One widely cited triage protocol is the Ottawa triage protocol, based on Sequential Organ Failure Assessment (SOFA) score cut-offs, which, in a simulated pandemic model, has been shown to potentially increase ICU bed availability by 53%.[@bib16] ^,^ [@bib17] A similar protocol utilising progressively more restrictive 'tiers' of criteria for non-initiation and withdrawal of intensive care, depending on resource scarcity, has been developed in Minnesota.[@bib18] More recently, ANZICS has released guidance to support the development of local admission policies, in the event that ICU demand outstrips supply during the COVID-19 pandemic.[@bib19] Other studies have demonstrated overall poorer outcomes with frailty in very old critically ill patients.[@bib8] ^,^ [@bib20] ^,^ [@bib21] Taken together, these studies suggest that measurement of frailty is important, but should perhaps be best considered in the context of other variables in making triage decisions.

The risk of death in our study for patients with a CFS of 4 was essentially identical to that observed with a CFS ≥5. Thus, one approach to substantially reduce ICU occupancy might be to reduce the ICU admission threshold to a CFS ≥4. Our data suggest that this approach would reduce total ICU bed occupancy by half, at the expense of not admitting many more patients with expected favourable outcomes. Alternatively, if triaging patient admissions purely on expected mortality, a threshold of a CFS ≥7 is more supported by our data. If multiple vulnerable or frail patients were being considered for the same ICU bed, our data suggest that factors other than the CFS (such as dynamic SOFA score assessments) should also be used to determine which patient is admitted to the ICU. Given that outcomes for CFS 4 and 5 patients were similar in our study, this would arguably be more equitable than the current approach being advocated by the National Institute for Health and Care Excellence.[@bib5]

Our study has numerous strengths, including the scale and scope of the registry used, which includes critically ill patients drawn from all states and territories in a bi-national contemporary cohort at a population level. The population studied was not restricted beyond admissions for palliative care, and thus represents a comprehensive overview of the prevalence and impact of frailty in ICU in Australia and New Zealand. A further strength is the frailty measure chosen, with the CFS having become the dominant tool for frailty assessment in critically ill patients. We have previously demonstrated that this scale has acceptable inter-individual variation in the critically ill population, and correlates well with more comprehensive frailty measurement scales.[@bib22] ^,^ [@bib23]

The major limitation of our study is that we studied patients with non-COVID pneumonia. As pulmonary infection with severe acute respiratory syndrome coronavirus 2 presents a novel disease, this presents challenges for extrapolating our findings from critically ill patients in Australia and New Zealand to patients with COVID-19 in the UK. However, reports of COVID-19 patients requiring critical care from Lombardy, Italy[@bib24] and Wuhan, China[@bib25] suggest that the characteristics of patients included in our study are similar to those seen in COVID-19 patients. We cannot preclude the possibility that the relationship between frailty and outcomes is different for patients with COVID-19 compared with other pneumonias. However, our contemporary cohort of patients with a range of bacterial and viral pneumonias found no evidence that the aetiology of pneumonia affected the association between frailty and outcomes. Emerging data have suggested that different phenotypes of COVID-19 might have different ventilator requirements.[@bib26] ^,^ [@bib27] However, we found no evidence that the relationship between frailty and outcomes was different for patients who were ventilated compared with those who were not. Frailty scores were missing for 35% of patients; extrapolation of our results to the whole population and to overall ICU bed-day occupancy could have hence been biased. Sensitivity analyses, however, revealed no major clinically significant differences between included and non-included patients, with no differences in either ICU or hospital length of stay likely to have changed percentages of bed-day occupancy within frailty categories. It would have been useful to have data on post-hospitalisation outcomes because it is possible that frailty may have been associated with late mortality as found in other studies.[@bib2] ^,^ [@bib22] We did not define the diagnostic criteria for bacterial or viral pneumonia beyond that of the APACHE III-j diagnostic codes. It is possible that misclassification thus occurred, although we note that this is a common limitation of registry studies. Data collectors used medical record review to determine the CFS scores, in contrast to prior studies.[@bib2] ^,^ [@bib6] Our prior work, however, has shown that CFS derivation from retrospective medical ICU chart review is feasible.[@bib23] Moreover, additional prior research has also demonstrated that CFS scores assigned in this manner correlate well with those determined through patient interview.[@bib28] We did not mandate formal training of frailty measurement in participating ICUs. Inaccurate scoring was hence possible; however, all data collection in the APD is conducted with reference to a data dictionary, with explicit instructions and definitions about the CFS measurement.

Conclusion {#sec5}
==========

Frailty is common in patients with pneumonia admitted to the ICU and is associated with in-hospital mortality. Mild frailty (CFS=5) was not more strongly associated with mortality than vulnerability (CFS=4), suggesting that CFS ≥5 may not define a suitable triage threshold based purely on expected mortality. Given only patients with severe and very severe frailty (CFS ≥7) had a higher risk of death over lower categories, with little extra ICU capacity resulting from exclusion of these patients, we advocate that factors other than the CFS (e.g. dynamic illness severity scoring) should also be considered in determining which patient is admitted to the ICU.
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